REGISTERED NUMBER: |
Trucs Therapeutics Limited |
Audited Financial Statements |
for the Year Ended 30 June 2024 |
REGISTERED NUMBER: |
Trucs Therapeutics Limited |
Audited Financial Statements |
for the Year Ended 30 June 2024 |
Trucs Therapeutics Limited (Registered number: 11749031) |
Contents of the Financial Statements |
for the year ended 30 June 2024 |
Page |
Company Information | 1 |
Balance Sheet | 2 |
Notes to the Financial Statements | 3 |
Trucs Therapeutics Limited |
Company Information |
for the year ended 30 June 2024 |
Directors: |
Secretary: |
Registered office: |
Registered number: |
Auditors: |
Statutory Auditor |
New Derwent House |
69-73 Theobalds Road |
London |
WC1X 8TA |
Trucs Therapeutics Limited (Registered number: 11749031) |
Balance Sheet |
30 June 2024 |
2024 | 2023 |
Notes | $ | $ |
Current assets |
Debtors | 4 |
Cash at bank |
Creditors |
Amounts falling due within one year | 5 |
Net current assets |
Total assets less current liabilities |
Capital and reserves |
Called up share capital | 6 |
Retained earnings | 7 |
Shareholders' funds |
The financial statements were approved by the Board of Directors and authorised for issue on |
Trucs Therapeutics Limited (Registered number: 11749031) |
Notes to the Financial Statements |
for the year ended 30 June 2024 |
1. | Statutory information |
Trucs Therapeutics Limited is a |
2. | Accounting policies |
Basis of preparing the financial statements |
The financial statements are prepared in US Dollars, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest $1. |
Basis other than going concern |
The directors concluded that the company is no longer a going concern. Accordingly these financial statements are prepared on a basis other than going concern. |
This basis includes, where applicable, writing the company's assets down to net realisable value. No provision has been made for the future costs of terminating the business unless such costs were committed at the reporting date. |
Taxation |
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
Current or deferred taxation assets and liabilities are not discounted. |
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
Trucs Therapeutics Limited (Registered number: 11749031) |
Notes to the Financial Statements - continued |
for the year ended 30 June 2024 |
2. | Accounting policies - continued |
Foreign exchange |
Transactions in currencies other than the functional currency (foreign currency) are initially recorded at the exchange rate prevailing on the date of the transaction. |
Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the reporting date. Non-monetary assets and liabilities denominated in foreign currencies are translated at the rate ruling at the date of the transaction, or, if the asset or liability is measured at fair value, the rate when that fair value was determined. |
All translation differences are taken to profit or loss, except to the extent that they relate to gains or losses on non-monetary items recognised in other comprehensive income, when the related translation gain or loss is also recognised in other comprehensive income. |
Financial instruments |
Financial assets and financial liabilities are recognised in the balance sheet when the company becomes a party to the contractual provisions of the instrument. |
Trade and other debtors and creditors are classified as basic financial instruments and measured at initial recognition at transaction price. Debtors and creditors are subsequently measured at amortised cost using the effective interest rate method. A provision is established when there is objective evidence that the company will not be able to collect all amounts due. |
Cash and cash equivalents are classified as basic financial instruments and comprise cash in hand and at bank and bank overdrafts which are an integral part of the company's cash management. |
Financial liabilities and equity instruments issued by the company are classified in accordance with the substance of the contractual arrangements entered into and the definitions of a financial liability and an equity instrument. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs. |
3. | Employees and directors |
The average number of employees during the year was NIL (2023 - NIL). |
4. | Debtors: amounts falling due within one year |
2024 | 2023 |
$ | $ |
Amounts owed by group undertakings |
VAT |
5. | Creditors: amounts falling due within one year |
2024 | 2023 |
$ | $ |
Trade creditors |
Tax |
Accruals and deferred income |
Trucs Therapeutics Limited (Registered number: 11749031) |
Notes to the Financial Statements - continued |
for the year ended 30 June 2024 |
6. | Called up share capital |
Allotted, issued and fully paid: |
Number: | Class: | Nominal | 2024 | 2023 |
value: | $ | $ |
Ordinary share capital | 1 | 121 | 121 |
7. | Reserves |
Retained |
earnings |
$ |
At 1 July 2023 |
Deficit for the year | ( |
) |
At 30 June 2024 |
8. | Disclosure under Section 444(5B) of the Companies Act 2006 |
The Auditors' Report was unqualified. |
for and on behalf of |
9. | Parent company |
The ultimate parent company and controlling party is Adaptimmune Therapeutics Plc. |